These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21071305)

  • 1. [Non-alcoholic steatosis/steatohepatitis -- 2010].
    Hagymási K; Lengyel G
    Orv Hetil; 2010 Nov; 151(47):1940-5. PubMed ID: 21071305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
    Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
    J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pathogenesis of non-alcoholic fatty liver and potential therapeutic targets].
    Crespo J; Cayón A; Pons-Romero F
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():15-23. PubMed ID: 15195530
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of fatty liver disease].
    Cobo Martín M; Fernández Gil P; Crespo J
    Gastroenterol Hepatol; 2008 Apr; 31(4):229-38. PubMed ID: 18405489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-alcoholic fatty liver disease.
    Tuyama AC; Chang CY
    J Diabetes; 2012 Sep; 4(3):266-80. PubMed ID: 22564417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Variants of the course of non-alcoholic fatty liver disease in patients with ischemic heart disease and possibility of hypolipidemic therapy].
    Kurliak NV
    Wiad Lek; 2014; 67(2 Pt 2):344-7. PubMed ID: 25796866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives.
    Federico A; Trappoliere M; Loguercio C
    Dig Liver Dis; 2006 Nov; 38(11):789-801. PubMed ID: 16750661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.
    Zaitone S; Hassan N; El-Orabi N; El-Awady el-S
    Eur J Pharmacol; 2011 Jul; 662(1-3):70-7. PubMed ID: 21549113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis.
    Beraza N; Malato Y; Vander Borght S; Liedtke C; Wasmuth HE; Dreano M; de Vos R; Roskams T; Trautwein C
    Gut; 2008 May; 57(5):655-63. PubMed ID: 18408102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of non-alcoholic fatty liver disease].
    Koek GH
    Ned Tijdschr Geneeskd; 2011; 155():A3181. PubMed ID: 21649947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM
    Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soy protein retards the progression of non-alcoholic steatohepatitis via improvement of insulin resistance and steatosis.
    Yang HY; Tzeng YH; Chai CY; Hsieh AT; Chen JR; Chang LS; Yang SS
    Nutrition; 2011 Sep; 27(9):943-8. PubMed ID: 21333494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of non-alcoholic steatohepatitis].
    Fehér J; Hagymási K
    Orv Hetil; 2004 Mar; 145(12):631-4. PubMed ID: 15119118
    [No Abstract]   [Full Text] [Related]  

  • 17. [Diagnosis and therapy in NASH].
    Tokushige K
    Rinsho Byori; 2009 Sep; 57(9):848-53. PubMed ID: 19860210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Common occurrence of non-alcoholic fatty liver disease and cholecystolithiasis].
    Fraenkel E; Takács R; Hamvas J; Lengyel G; Fehér J
    Orv Hetil; 2007 Apr; 148(17):793-8. PubMed ID: 17452309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Non-alcoholic fatty liver disease in dyslipidemia and insulin resistance: similarities and differences; differential approach to therapy].
    Lazebnik LB; Zvenigorodskaia LA; Egorova EG; Mel'nikova NV; Khomeriki SG
    Eksp Klin Gastroenterol; 2009; (8):4-11. PubMed ID: 20469672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic fatty liver disease in children.
    Janczyk W; Socha P
    Clin Res Hepatol Gastroenterol; 2012 Jun; 36(3):297-300. PubMed ID: 22521558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.